

SCHEDULE 13G

Amendment No. 0

LEAP THERAPEUTICS INC  
COMMON STOCK

Cusip #52187K101

Check the appropriate box to designate the rule pursuant to which this

Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

Cusip #52187K101

Item 1: Reporting Person - FMR LLC

Item 2: (a)

(b)

Item 4: Delaware

Item 5: 0

Item 6: 0

Item 7: 957,124

Item 8: 0

Item 9: 957,124

Item 11: 6.509%

Item 12: HC

Cusip #52187K101

Item 1: Reporting Person - Abigail P. Johnson

Item 2: (a)

(b)

Item 4: United States of America

Item 5: 0

Item 6: 0

Item 7: 957,124

Item 8: 0

Item 9: 957,124

Item 11: 6.509%

Item 12: IN

Cusip #52187K101

Item 1: Reporting Person - Select Biotechnology Portfolio

Item 2: (a)

(b)

Item 4: Massachusetts

Item 5: 840,724

Item 6: 0

Item 7: 0

Item 8: 0

Item 9: 840,724

Item 11: 5.717%

Item 12: IV

Item 1(a). Name of Issuer:

LEAP THERAPEUTICS INC

Item 1(b). Address of Issuer's Principal Executive Offices:

47 THORNDIKE STREET, SUITE B1-1

CAMBRIDGE, MA 02142

USA

Item 2(a). Name of Person Filing:

FMR LLC

Item 2(b). Address or Principal Business Office or, if None, Residence:

245 Summer Street, Boston, Massachusetts 02210

Item 2(c). Citizenship:

Not applicable

Item 2(d). Title of Class of Securities:

COMMON STOCK

Item 2(e). CUSIP Number:

52187K101

Item 3. This statement is filed pursuant to Rule 13d-1(b) or 13d-2(b) or (c) and the person filing, FMR LLC, is a parent holding company in accordance with Section 240.13d-1(b)(1)(ii)(G). (Note: See Exhibit A).

Item 4. Ownership

(a) Amount Beneficially Owned: 957,124

(b) Percent of Class: 6.509%

(c) Number of shares as to which such person has:

(i) sole power to vote or to direct the vote: 0

(ii) shared power to vote or to direct the vote: 0

(iii) sole power to dispose or to direct the disposition of: 957,124

(iv) shared power to dispose or to direct the disposition of: 0

Item 5. Ownership of Five Percent or Less of a Class.

Not applicable.

Item 6. Ownership of More than Five Percent on Behalf of Another Person.

One or more other persons are known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the COMMON STOCK of LEAP THERAPEUTICS INC. No one other person's interest in the COMMON STOCK of LEAP THERAPEUTICS INC is more than five percent of the total outstanding COMMON STOCK.

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

See attached Exhibit A.

Item 8. Identification and Classification of Members of the Group.

Not applicable.

Item 9. Notice of Dissolution of Group.

Not applicable.

Item 10. Certifications.

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

Signature

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

February 13, 2019

Date

/s/ Kevin M. Meagher  
Signature

Kevin M. Meagher

Duly authorized under Power of Attorney effective as of September 28, 2018, by  
and on behalf of FMR LLC and its direct and indirect subsidiaries\*

\* This power of attorney is incorporated herein by reference to Exhibit 24 to  
the Schedule 13G filed by FMR LLC on October 9, 2018, accession number:  
0000315066-18-002414.

Exhibit A

Pursuant to the instructions in Item 7 of Schedule 13G, the following table  
lists the identity and Item 3 classification, if applicable, of each relevant  
entity that beneficially owns shares of the security class being reported on  
this Schedule 13G.

Entity	ITEM 3 Classification
--------	-----------------------

FMR CO., INC	* IA
--------------	------

\* Entity beneficially owns 5% or greater of the outstanding shares of the  
security class being reported on this Schedule 13G.

Abigail P. Johnson is a Director, the Chairman and the Chief Executive Officer  
of FMR LLC.

Members of the Johnson family, including Abigail P. Johnson, are the  
predominant owners, directly or through trusts, of Series B voting common  
shares of FMR LLC, representing 49% of the voting power of FMR LLC. The  
Johnson family group and all other Series B shareholders have entered into a  
shareholders' voting agreement under which all Series B voting common shares  
will be voted in accordance with the majority vote of Series B voting common  
shares. Accordingly, through their ownership of voting common shares and the  
execution of the shareholders' voting agreement, members of the Johnson family  
may be deemed, under the Investment Company Act of 1940, to form a controlling  
group with respect to FMR LLC.

Neither FMR LLC nor Abigail P. Johnson has the sole power to vote or direct  
the voting of the shares owned directly by the various investment companies  
registered under the Investment Company Act ("Fidelity Funds") advised by  
Fidelity Management & Research Company ("FMR Co"), a wholly owned subsidiary  
of FMR LLC, which power resides with the Fidelity Funds' Boards of Trustees.  
FMR Co carries out the voting of the shares under written guidelines  
established by the Fidelity Funds' Boards of Trustees.

This filing reflects the securities beneficially owned, or that may be deemed  
to be beneficially owned, by FMR LLC, certain of its subsidiaries and  
affiliates, and other companies (collectively, the "FMR Reporters"). This  
filing does not reflect securities, if any, beneficially owned by certain  
other companies whose beneficial ownership of securities is disaggregated from  
that of the FMR Reporters in accordance with Securities and Exchange  
Commission Release No. 34-39538 (January 12, 1998).

RULE 13d-1(k)(1) AGREEMENT

The undersigned persons, on February 13, 2019, agree and consent to the joint  
filing on their behalf of this Schedule 13G in connection with their  
beneficial ownership of the COMMON STOCK of LEAP THERAPEUTICS INC at December  
31, 2018.

FMR LLC

By /s/ Kevin M. Meagher  
Kevin M. Meagher

Duly authorized under Power of Attorney effective as of September 28, 2018, by and on behalf of FMR LLC and its direct and indirect subsidiaries\*

Abigail P. Johnson

By /s/ Kevin M. Meagher  
Kevin M. Meagher

Duly authorized under Power of Attorney effective as of September 30, 2018, by and on behalf of Abigail P. Johnson\*

Select Biotechnology Portfolio

By /s/ Kevin M. Meagher  
Kevin M. Meagher

Duly authorized under Power of Attorney\*

\* This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on October 9, 2018, accession number: 0000315066-18-002414.